Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Recruiting

Phase 1

²¹²Pb-DOTAM-GRPR1Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Sponsor:

Orano Med LLC

Code:

NCT05283330

Conditions

Cervical Cancer

Prostate Cancer Metastatic

Breast Cancer

Colon Cancer

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

²¹²Pb-DOTAM-GRPR1

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-10. This information was provided to ClinicalTrials.gov by Orano Med LLC on 2023-10-19.